Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nova Eye Medical ( (AU:EYE) ) just unveiled an announcement.
Nova Eye Medical has scheduled an investor webinar for Monday, 19 January 2026 at 11:30 am AEDT, during which Managing Director Tom Spurling will present a sales update for the six months ended 31 December 2025 and take questions from participants. The event signals an effort by the glaucoma-focused device maker to increase transparency and engagement with shareholders ahead of releasing detailed half-year figures, offering investors an early window into trading performance and operational momentum in its key markets.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
More about Nova Eye Medical
Nova Eye Medical Limited is a medical technology company focused on developing, manufacturing and selling proprietary ophthalmic treatment technologies and devices used by eye surgeons worldwide. Its portfolio includes the iTrack Advance minimally invasive glaucoma surgical device for mild to moderate glaucoma, designed to restore the eye’s natural outflow pathway and reduce reliance on medication, and the Molteno3 glaucoma drainage device platform for severe glaucoma, aimed at improving long-term intraocular pressure control with a simplified, faster surgical procedure. The company operates sales headquarters in Fremont, California, supported by a global distributor network, with manufacturing facilities in Fremont, California, and Dunedin, New Zealand.
Average Trading Volume: 292,240
Technical Sentiment Signal: Buy
Current Market Cap: A$49.85M
Find detailed analytics on EYE stock on TipRanks’ Stock Analysis page.